Ionis Pharmaceuticals, Inc.

NasdaqGS:IONS 株式レポート

時価総額:US$5.9b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Ionis Pharmaceuticals 過去の業績

過去 基準チェック /06

Ionis Pharmaceuticalsの収益は年間平均-49.8%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間15.5% 5.6%割合で 減少しています。

主要情報

-49.8%

収益成長率

-49.7%

EPS成長率

Biotechs 業界の成長17.0%
収益成長率-5.6%
株主資本利益率-129.8%
ネット・マージン-49.5%
前回の決算情報31 Mar 2024

最近の業績更新

Recent updates

Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism

May 28

Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report

May 09
Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report

Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S

Apr 14
Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Mar 18
Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain

Feb 23

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected

Dec 28
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected

Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Dec 07
Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

A Look At The Intrinsic Value Of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Nov 16
A Look At The Intrinsic Value Of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Aug 03
Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

May 05
Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet?

Jan 20
Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet?

Ionis Pharmaceuticals Looks Good For The Long Term

Oct 19

Ionis plans for new manufacturing site in California to support pipeline

Oct 13

Ionis: 2 Drug Advancements With Potential Firsts

Aug 29

Ionis Pharmaceuticals Q2 2022 Earnings Preview

Aug 08

Ionis Pharmaceuticals (NASDAQ:IONS) Could Easily Take On More Debt

Aug 08
Ionis Pharmaceuticals (NASDAQ:IONS) Could Easily Take On More Debt

Ionis Pharma: Too Many Programs Have Failed To Produce Confidence

Jun 15

Is Ionis Pharmaceuticals (NASDAQ:IONS) Weighed On By Its Debt Load?

Apr 06
Is Ionis Pharmaceuticals (NASDAQ:IONS) Weighed On By Its Debt Load?

Ionis Pharmaceuticals: Finding Financial Value In Biotech Research

Mar 27

Ionis: At A Show-Me Crossroads

Mar 14

Some Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Analysts Just Made A Major Cut To Next Year's Estimates

Feb 25
Some Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Analysts Just Made A Major Cut To Next Year's Estimates

収支内訳

Ionis Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqGS:IONS 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
31 Mar 24777-3852200
31 Dec 23788-3662130
30 Sep 23615-4092100
30 Jun 23631-3091740
31 Mar 23576-3291620
31 Dec 22587-2701500
30 Sep 2287571410
30 Jun 22849-281370
31 Mar 22841-41480
31 Dec 21810-291860
30 Sep 21661-6082070
30 Jun 21688-5502450
31 Mar 21708-4952720
31 Dec 20729-4443540
30 Sep 20933942990
30 Jun 209401452900
31 Mar 209591692930
31 Dec 191,1232812870
30 Sep 198214332690
30 Jun 197994022780
31 Mar 197523662690
31 Dec 186002772450
30 Sep 18575-412240
30 Jun 18548-381820
31 Mar 1854391380
31 Dec 17514191080
30 Sep 1750742810
30 Jun 1749952640
31 Mar 17426-15520
31 Dec 16373-60490
30 Sep 16238-184440
30 Jun 16176-227420
31 Mar 16258-134400
31 Dec 15284-88370
30 Sep 1531714310
30 Jun 1531223270
31 Mar 15249-24230
31 Dec 14214-39200
30 Sep 14172-94180
30 Jun 14151-92170
31 Mar 14132-90160
31 Dec 13147-61150
30 Sep 13125-39130
30 Jun 13113-52100

質の高い収益: IONSは現在利益が出ていません。

利益率の向上: IONSは現在利益が出ていません。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: IONSは利益が出ておらず、過去 5 年間で損失は年間49.8%の割合で増加しています。

成長の加速: IONSの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: IONSは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -14.4% ) と比較することは困難です。


株主資本利益率

高いROE: IONSは現在利益が出ていないため、自己資本利益率 ( -129.76% ) はマイナスです。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘